For clinical applications, the detection of LARP4B expression in HCC tissues could predict the efficacy of sorafenib treatment, and HCC patients with higher expression of LARP4B should receive an increased dosage of sorafenib. The gene discussed is LARP4B; the disease is hepatocellular carcinoma.